American Heart Journal
Volume 157, Issue 3 , Pages 457-466 , March 2009

Effects of cardiac resynchronization therapy on long-term quality of life: An analysis from the CArdiac Resynchronisation-Heart Failure (CARE-HF) study

  • John G.F. Cleland, MD

      Affiliations

    • Department of Cardiology, University of Hull, Castle Hill Hospital, Kingston upon Hull, United Kingdom
    • Corresponding Author InformationReprint requests: John G. F. Cleland, Department of Cardiology, University of Hull HU16 5JQ, Castle Hill Hospital, Kingston upon Hull, United Kingdom.
    • ,
  • Melanie J. Calvert, PhD

      Affiliations

    • Department of Primary Care and General Practice, University of Birmingham, Birmingham, United Kingdom
    • ,
  • Yves Verboven, MScEng

      Affiliations

    • Medtronic Inc., Bakken Research Centre, Maastricht, The Netherlands
    • ,
  • Nick Freemantle, PhD

      Affiliations

    • Department of Primary Care and General Practice, University of Birmingham, Birmingham, United Kingdom

Received 12 February 2008 ,Accepted 13 November 2008.

References 

  1. Cleland JGF. How to assess new treatments for the management of heart failure: composite scoring systems to assess the patients' clinical journey. Eur J Heart Fail. 2002;4:243–247
  2. Rector TS, Tschumperlin LK, Kubo SH, et al. Use of the living with heart failure questionnaire to ascertain patients' perceptives on improvement in quality of life versus risk of drug-induced death. J Card Fail. 1995;1:201–206
  3. Lewis EF, Johnson PA, Johnson W, et al. Preferences for quality of life or survival expressed by patients with heart failure. J Heart Lung Trans. 2001;20:1016–1024
  4. Hobbs FDR, Kenkre JE, Roalfe AK, et al. Impact of heart failure and left ventricular systolic dysfunction on quality of life. A cross-sectional study comparing common chronic cardiac and medical disorders and a representative adult population. Eur Heart J. 2002;23:1867–1876
  5. Juenger J, Schellberg D, Kraemer S, et al. Health related quality of life in patients with congestive heart failure: comparison with other chronic diseases and relation to functional variables. Heart. 2002;87:235–241
  6. Stewart AL, Greenfled S, Hays RD, et al. Functional status and wellbeing of patients with chronic conditions. Results from the medical outcomes study. JAMA. 1989;262:907–913
  7. Ekman I, Fagerberg B, Lundman B. Health-related quality of life and sense of coherence among elderly patients with severe chronic heart failure in comparison with healthy controls. Heart & Lung: J Acute Crit Care. 2002;31:94–101
  8. Calvert MJ, Freemantle N, Cleland JGF. The impact of chronic heart failure on health-related quality of life data acquired in the baseline phase of the CARE-HF Study. Eur J Heart Fail. 2005;7:243–251
  9. Abraham WT, Fisher WG, Smith AL, et al. for the MIRACLE Study Group Cardiac resynchronisation in chronic heart failure. N Engl J Med. 2002;346:1845–1853
  10. Bristow MR, Saxon LA, Boehmer J, et al. for the comparison of medical therapy padihfCi Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140–2150
  11. Cazeau S, Leclerc C, Lavergne T, et al. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med. 2001;344:873–880
  12. Cleland JGF, Daubert J-C, Erdmann E, et al. for the Cardiac Resynchronisation-Heart Failure (CARE-HF) Study Investigators The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352:1539–1549
  13. Gras D, Lunati M, Wellens HJJ, et al. Implantation of cardiac resynchronization therapy systems in the CARE-HF trial: procedural success rate and safety. Europace. 2007;9:516–522
  14. Cleland JGF, Daubert JC, Erdmann E, et al. Design and methodology of the CARE-HF trial. A randomised trial of cardiac resynchronisation in patients with heart failure and ventricular dyssynchrony. Eur J Heart Fail. 2001;3:481–489
  15. Cleland JG, Daubert JC, Erdmann E. Baseline characteristics of patients recruited into the CARE-HF study. Eur J Heart Fail. 2005;7:205–214
  16. Rector TS, Cohn JN. Assessment of patient outcome with the Minnesota Living with Heart Failure Questionnaire: Reliability and validity during a randomized, double-blind placebo-controlled trial of pimobendan. Am Heart J. 1992;124:1017–1025
  17. EQ-5D. Measure of health-related quality of life developed by the Euroqol Group. Available at: http://www.euroqol.org. Last accessed January 4, 2009.
  18. Dolan P. Modeling valuations for Euroqol health states. Med Care. 1997;35:1095–1108
  19. Kind P, Hardman G, Macran S. UK population norms for EQ-5D. York, United Kingdom: University of York Press; 1999;[Discussion Paper 172.
  20. Badia X, Roset M, Herdman M. A comparison of United Kingdom and Spanish General Population Time Trade-off Values for EQ-5D Health States. Med Decis Making. 2001;21:7–16
  21. Nyman JA, Barleen NA, Dowd BE. Quality-of-life weights for the US population: self-reported health status and priority health conditions, by demographic characteristics. Med Care. 2007;45:618–628
  22. Sullivan PW, Lawrence WF, Ghushchyan V. A national catalog of preference-based scores for chronic conditions in the United States. Med Care. 2005;43:736–749
  23. Greiner W, Claes C, Busschbach JJV, et al. Validating the EQ-5D with time trade off for the German population. Eur J Health Econ. 2005;6:124–130
  24. Value sets produced as part of the EuroQol Group enterprise. Available at: http://www.euroqol.org. Last accessed January 4, 2009.
  25. Johnson J, Luo N, Shaw J, et al. Valuations of EQ-5D health states: are the United States and United Kingdom different. Med Care. 2005;43:221–228
  26. Lewis JA. ICH harmonised tripartite guideline. statistical principles for clinical trials (ICH E9). Stat Med. 1999;18:1905–1942
  27. Harrell FE, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15:361–387
  28. Walters SJ, Brazier JE. Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Qual Life Res. 2005;14:1523–1532
  29. Rogers WJ, Johnstone DE, Yusuf S. Quality of life among 5025 patients with left ventricular dysfunction randomised between placebo and enalapril. The Studies Of Left-Ventricular Dysfunction. J Am Coll Cardiol. 1994;23:393–400
  30. Lader E, Egan D, Hunsberger S, et al. The effect of digoxin on the quality of life in patients with heart failure. J Cardiac Failure. 2008;9:4–12
  31. Fowler MB. Effects of beta blockers on symptoms and functional capacity in heart failure. Am J Cardiol. 1997;80:55L–58L
  32. Majani G, Giardini A, Opasich C, et al. Effect of valsartan on quality of life when added to usual therapy for heart failure: results from the valsartan heart failure trial. J Card Fail. 2005;11:253–259
  33. Cleland JGF, Daubert JC, Erdmann E, et al. Longer-term effects of cardiac resynchronization therapy on mortality in heart failure. The CARE-HF trial extension phase. Eur Heart J. 2006;27:1928–1932
  34. Machin D, Campbell M, Fayers P, et al. Sample size tables for clinical studies. 2nd ed.. Oxford, England: Blackwell Science; 1997;
  35. Friedman MM. Gender differences in the health related quality of life of older adults with heart failure. Heart Lung: J Acute Crit Care. 2003;32:320–327
  36. Stromberg A, Martensson J. Gender differences in patients with heart failure. J Cardiovasc Nurs. 2003;2:7–18
  37. Haworth JE, Moniz-Cook E, Clark AL, et al. Prevalence and predictors of anxiety and depression in a sample of chronic heart failure patients with left ventricular systolic dysfunction. Eur J Heart Fail. 2005;7:803–808
  38. Godfrey CM, Harrison MB, Friedberg E, et al. The symptom of pain in individuals recently hospitalized for heart failure. J Cardiovasc Nurs. 2007;22:368–374
  39. Hoppe UC, Casares JM, Eiskjaer H, et al. Effect of cardiac resynchronization on the incidence of atrial fibrillation in patients with severe heart failure. Circulation. 2006;114:18–25
  40. Cleland JGF, Charlesworth A, Lubsen J, et al. A comparison of the effects of carvedilol and metroprolol on “well-being,” morbidity and mortality (the patient journey) in patients with heart failure: a report from the Carvedilol or Metoprolol European Trial (COMET). J Am Coll Cardiol. 2006;47:1603–1611
  41. Yao G, Freemantle N, Calvert M, et al. The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator. Eur Heart J. 2007;28:42–51
  42. Cleland JGF, Nasir M, Tageldien A. Cardiac resynchronization therapy or atriobiventricular pacing—what should it be called. Natl Clin Pract Cardiovasc Med. 2007;4:90–101
  43. Cleland JGF, Coletta AP, Clark AL. Clinical trials update from the Heart Failure Society of America Meeting: FIX-CHF-4, selective cardiac myosin activator and OPT-CHF. Eur J Heart Fail. 2006;8:764–766
  44. Cleland JGF, Louis AA, Rigby AS, et al. on behalf of the TEN-HMS investigators Noninvasive home telemonitoring for patients with heart failure at high risk of recurrent admission and death. J Am Coll Cardiol. 2005;45:1654–1664

PII: S0002-8703(08)00983-6

doi: 10.1016/j.ahj.2008.11.006

American Heart Journal
Volume 157, Issue 3 , Pages 457-466 , March 2009

Article Tools

* Image Usage & Resolution